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New strategies are being devised to limit the impact of renal sclerosis on graft function. Individualization of immunosuppression,
specifically the interruption of calcineurin-inhibitors has been tried in order to promote better graft survival once chronic graft
dysfunction has been established. However, the long-term impact of these approaches is still not totally clear. Nevertheless,
patients at higher risk for tubular atrophy and interstitial fibrosis (TA/IF) development should be carefully monitored for tubular
function as well as glomerular performance. Since tubular-interstitial impairment is an early event in TA/IF pathogenesis and
associated with graft function, it seems reasonable that strategies directed at assessing tubular structural integrity and function
would yield important functional and prognostic data. The measurement of small proteins in urine such as α-1-microglobulin, N-
acetyl-beta-D-glucosaminidase, alpha/pi S-glutathione transferases, β-2 microglobulin, and retinol binding protein is associated
with proximal tubular cell dysfunction. Therefore, its straightforward assessment could provide a powerful tool in patient
monitoring and ongoing clinical assessment of graft function, ultimately helping to facilitate longer patient and graft survival
associated with good graft function.
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Introduction
Long-term kidney allograft survival is reduced by the
unavoidable occurrence of tissue fibrosis, namely, glomer-
ulosclerosis, tubular atrophy and interstitial fibrosis (TA/
IF). Since 1991 this condition has been known as chronic
allograft nephropathy. However, chronic allograft nephrop-
athy involves not only a chronic rejection diagnosis but
also other entities that culminate with glomerulosclerosis
and TA/IF such as chronic drug toxicity. The present article
will consider a broader definition of this condition because
many immune and non-immune factors are implicated in
its pathogeny. Although much attention has been directed
towards the individualization of immunosuppressive drugs
once TA/IF has been diagnosed, little data are available
showing the real long-term benefit of this strategy. There-
fore, a more plausible approach to improve post-transplant
graft survival would be the very early detection of TA/IF.
Taking into consideration the physiological events that
occur during development of graft fibrosis, we have pro-
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posed that early detection of proximal tubular cell dysfunc-
tion by urinary measurement of small proteins may offer a
reliable and sensitive means of predicting long-term graft
function. Here we review the concept underlying this hypo-
thesis and presented the rationale for monitoring proximal
tubular cell dysfunction in kidney allografts.
Many roads to Rome: the undesirable natural
history of chronic graft dysfunction
In renal transplantation, the UNOS/OPTN registry data
demonstrate a long-term graft loss rate of at least 40% at
the 10-year follow-up time-point. This attrition is due mainly
to two distinct conditions: death with a functioning graft and
chronic graft dysfunction. These observations have been
confirmed by recent analyses, where TA/IF stands as one
of the most frequent causes of initiation of dialysis in the
United States (1).
It is noteworthy that traditional outcome measures used
to define allograft performance have been evolving over
the past two decades. For example, in the pre-cyclo-
sporine era, graft survival at one year was a benchmark
measure. However, after the introduction of this calcineu-
rin inhibitor (CI), there were marked improvements in 1-
year graft survival (1,2). Subsequent to cyclosporine, in
the 1990’s, other milestones were reached, such as the
rates of acute rejection (AR) to name but one example.
Again, with the advent of potent, late-generation immuno-
suppressant agents - e.g., mycophenolate mofetil, tacroli-
mus, and induction therapy with antithymocyte agents - AR
episodes eventually fell below a threshold of about 10 to
20% in most transplant centers (3). Therefore, AR events
became outmoded as less robust measures of graft perfor-
mance.
We are left, therefore, with a powerful paradox: despite
improved immediate allograft performance as manifested
by low rates of early acute rejection and excellent 1-year
graft survival, long-term graft survival remains unaccept-
ably compromised. Simply put: all renal allografts fail over
time. This is largely due to TA/IF, which may be caused by
long-term exposure to the lynchpins of immunosuppres-
sive protocols, CI, viral infection (polyomavirus: BK virus),
acute/subclinical rejection, ischemia and reperfusion in-
jury, dyslipidemia/hypertension/diabetes, among others.
To date, there are no reliable tests that can predict the
development of chronic allograft dysfunction, while a ge-
nomic approach has been investigated in order to detect it.
Because long-term graft decline has been the rule in
kidney transplantation, there is a great need for the devel-
opment of an index or marker that could be associated with
long-term kidney allograft survival and performance.
It is broadly accepted today that TA/IF comprises dis-
tinct entities that are joined in a final common pathway due
to the presence of tubulointerstitial fibrosis, glomeruloscle-
rosis and vasculopathy (4). Nevertheless, the real contri-
bution of drug toxicity, potentially hyperfiltration-mediated
glomerulosclerosis resulting from nephron overload, and
immune-mediated chronic rejection to tissue fibrosis is
hardly measurable. Although, as stated earlier, the histo-
logical features of TA/IF can be seen in glomeruli, vessels
and tubulointerstitium, its severity is graded mainly by the
degree of TA and IF. The decrease in graft function in
patients with graft fibrosis is mainly associated with the
amount of TA/IF (4,5).
Data from protocol biopsies suggest that the histologi-
cal features of graft fibrosis can be detected early, even as
early as 3 months post-transplantation; however, the nega-
tive impact on graft function may be evident in measurable
terms only late in the course. Once significant fibrosis and
associated TA/IF, as well as fall-out begin to affect renal
function, the clinical presentation is variable, with patients
presenting a range of clinical manifestations including
proteinuria, hypertension, and renal insufficiency. Recently,
Nankivell et al. (6) described the natural history of TA/IF,
demonstrating that it develops during the first 6 months
post-transplantation. These observations support the view
that there are two phases in graft fibrosis development: the
first phase is characterized by early tubulointerstitial dam-
age, caused by ischemia/reperfusion injury and subclinical
rejection and the later phase is chiefly characterized by
microvascular and glomerular injury. Thus, TA/IF can be
detected by protocol biopsies and its features correlated
with long-term graft function. These sequential biopsy data
also show that tubulointerstitial damage presages future
renal sclerosis.
Our objective in this review, is to demonstrate the
importance of tubule dysfunction in the development of
graft fibrosis, and, most importantly, to show how this
phenomenon can be exploited to monitor patients at high
risk for developing the dysfunction.
The epithelial-to-mesenchymal transition in
renal tubular cells
Ischemic and reperfusion injury (IRI) represents the
earliest danger sign for tubular cells (7,8). It has become
increasingly clear that IRI not only promotes acute suble-
thal injury but also induces a chronic inflammatory cas-
cade that ultimately leads to graft fibrosis. Early studies by
Tilney et al. (9) have demonstrated persistent infiltration of
macrophages and pro-inflammatory cytokines in isografts
compared to sham-operated control animals. More re-
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cently, Burne-Taney et al. (10) demonstrated that increased
myeloperoxidase activity and CD4+ T lymphocyte infiltra-
tion persist as late as 6 weeks after IRI, in association with
substantial chemokine production. Furthermore, those kid-
neys exposed to IRI developed interstitial fibrosis.
The causal relationship between ischemia and tissue
fibrosis came to light recently when several groups demon-
strated that proximal tubular cells exposed to a variety of
hypoxic conditions secrete chemokines that promote mon-
onuclear infiltration. This early infiltration by macrophages,
monocytes and T cells produces pro-fibrotic cytokines that
activate other cells, including resident fibroblasts. Further-
more, injured proximal tubular cells can be differentiated
into mesenchymal cells (11). During normal renal embryo-
genesis, mesenchymal-to-epithelial transition is obligatory
for normal development. We have observed an inverse
developmental transition associated with graft fibrosis,
namely an epithelial-to-mesenchymal transition (EMT).
EMT is a process whereby fully differentiated epithelial
cells undergo transition to a mesenchymal phenotype
giving rise to fibroblasts and myofibroblasts (12-14).
Experimentally, in renal fibrogenesis, it has been shown
that some new fibroblasts are derived from tubular cells
through EMT (11). The key cellular mediators of fibrosis
are the myofibroblasts, which when activated serve as the
primary collagen-producing cells. Myofibroblasts are gen-
erated from a variety of sources including resident mesen-
chymal cells, epithelial and endothelial cells, as well as
from circulating fibroblast-like cells called fibrocytes that
are derived from bone marrow stem cells (15). Much of the
matrix is synthesized by interstitial myofibroblasts, re-
cruited from resident fibroblasts and circulating precur-
sors. In addition, a significant proportion is derived from
EMT of tubule epithelial cells. The importance of EMT has
been demonstrated in experimental models, where block-
ade of EMT attenuates renal fibrosis (16,17).
Tubular EMT is an orchestrated, highly regulated pro-
cess, involving loss of epithelial cell adhesion molecules
and de novo mesenchymal-related molecule, such as
vimentin or S100A expression. Many factors can initiate
EMT, but transforming growth factor-β (TGF-β) is the most
potent. Signaling events in this pathway include activation
of Smad/integrin-linked kinase and connective tissue growth
factor (CTGF). Basement integrity is also a key regulator of
EMT (18). During this process, the epithelial cells lose
epithelial markers (cytokeratin, E-cadherin), apical-basal
polarity and cell surface microvilli and acquire mesenchy-
mal phenotype and fibrosing properties, as evidenced by
the expression of vimentin, types I, III and IV collagen, and
the collagen-synthesis chaperone protein, Hsp47. After
injury, the detachment of the epithelial cells from the base-
ment membrane leads to inhibition of type IV collagen
assembly, probably by the α1NC1 domain, and up-regula-
tion of TGF-β. Up-regulation of matrix metalloproteases
can also contribute to rupture of the tubular membrane, a
critical event in EMT. These data agree with those previ-
ously described by Bonsib et al. (19). During this process,
the epithelial tubular cells gain migratory properties and
invade the surrounding tissues.
TGF-β is believed to be a critical fibrogenic factor. In
vitro, TGF-β reversibly decreases expression of the epi-
thelial markers, increases expression of mesenchymal
ones, and plays a key role in the reorganization of actin
fibers. TGF-β can also modify the epithelial cell function-
ally, by down-regulating the megalin-cubilin-mediated en-
docytic apparatus. TGF-β effectively suppresses E-cad-
herin expression in vitro. This means that epithelial cells
will lose nearby cell contacts, structural integrity and cell
polarity.
CTGF mediates the downstream pro-fibrotic and dys-
functional actions of TGF-β and is highly expressed by
tubular epithelial cells engulfed by interstitial fibrosis. There
is increasing evidence suggesting that CTGF per se is
involved in EMT. CTGF is a 38-kDa heparin-binding cys-
teine-rich secreted extracellular matrix-associated protein
involved in the synthesis of collagen, myofibroblast differ-
entiation and cell proliferation, migration and adhesion
(18). Recently, Liu et al. (16) demonstrated that proximal
tubular cells cultivated in the presence of CTGF up-regu-
late alpha smooth muscle actin (α-SMA) and decrease E-
cadherin expressions. In another study, Cheng et al. (20)
determined the role of CTGF as a biomarker of kidney graft
fibrosis. These investigators demonstrated that the CTGF
was increased and up-regulated inside the graft, co-local-
ized with α-SMA in tubule epithelial cells, in a mouse model
of kidney transplantation. Moreover, in vitro studies re-
vealed that CTGF itself could induce EMT, independent of
TGF-β. Finally, they demonstrated that high urinary levels
of CTGF were present in patients with TA/IF and demon-
strated good correlation with the histology. Taken together,
these data demonstrated the potential of CTGF as a
biomarker of TA/IF and possibly of renal fibrosis. Another
growth factor, the tubular cell-derived, platelet-derived
growth factor also promotes fibroblast proliferation (15).
Studying the role of EMT in vivo, Strutz et al. (21)
demonstrated that tubular cells can express a fibroblast
marker, fibroblast specific protein 1 (FSP-1) in an anti-
membrane glomerulonephritis model. FSP-1 has been
associated with EMT and fibrosis. Rossini et al. (22) stud-
ied this marker in renal transplant biopsies. They found
that FSP-1 was expressed more in the interstitium in cells
with fibroblast-like morphology. Hertig et al. (23) studied
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the presence of EMT in biopsies of renal transplant pa-
tients 3 months after engraftment. In summary, they ob-
served that in 41% of grafts, tubular epithelial cell exhibited
mesenchymal transition markers, defined as vimentin-
positive cells and cytoplasm positive staining for beta-
catenin, in the absence of acute graft dysfunction and
advanced TA/IF. Their data suggest that EMT is an early
phenomenon. Vongwiwatana et al. (24) demonstrated that
tubular epithelial cells lose epithelial markers, such as E-
cadherin, and present vimentin, S100A4 and α-SMA in
biopsies of patients with TA/IF. More importantly, these
markers correlated with renal function.
The link between acute rejection and the development
of fibrosis was partially confirmed by a study carried out by
Robertson et al. (25). They demonstrated that S100A4, a
marker of EMT, co-localized with CD8+ T cell infiltration,
thus establishing a link between inflammation and EMT.
Early on, the same group had demonstrated that TGF-β
could indeed stimulate the expression of CD103 (αEβ7
integrin) in CD8+ T cells, the receptor of E-cadherin in
tubular cells, upon which these cells can directly induce
adjacent tubular epithelial cells to transform into proliferat-
ing fibroblasts that migrate across the tubular basement
membrane, producing fibrotic lesions within the renal inter-
stitium (26).
In the transplantation field, EMT can be induced by a
wide range of injuries, such as immunosuppressive drugs
(27), oxidative stress (28), acute rejection and, possibly,
viral infection (29). Immunosuppressive drugs can induce
or prevent EMT. Cyclosporine is associated with EMT in
human proximal tubular cells via the TGF-β/CTGF signal-
ing pathway (30,31). Recently, Copeland et al. (27) dem-
onstrated that rapamycin and mycophenolate mofetil actu-
ally prevented and even reversed EMT in vitro.
It is noteworthy that EMT is a regulated process and
proceeds mainly in a manner counteracting the physi-
ologic effects of TGF-β. Experimental data show that bone
morphogenic protein-7 (BMP-7) and hepatocyte growth
factor can both reverse EMT in vitro and in vivo (32). BMP-
7, a 35-kDa homodimeric protein and a member of the
TGF-β superfamily, can preserve and even restore renal
histology and function in different animal models of fibro-
sis. Therapeutic strategies that effect regression of renal
fibrosis include angiotensin II inhibition, endothelin an-
tagonism and BMP-7 treatment in various animal mod-
els of renal fibrosis.
Although these data have been derived primarily from
experimental rodent models, human clinical data have also
been generated that reveal a variety of potentially important
strategies to slow the progress of graft fibrosis. There are
increasing reports showing some improvement or preserva-
tion of graft function following decrease or withdrawal of CI
and the addition of mycophenolate mofetil or rapamycin, and
with strict control of dyslipidemia and hypertension. None-
theless, it has become clear that the best way to “treat” graft
fibrosis involves early diagnosis and intervention, before
important key steps in tissue fibrosis and tubular atrophy
take place. Because TA/IF primarily affects the tubulointer-
stitial compartment, one hypothesis is that it can be detected
by measuring small tubular proteins such as α-1-micro-
globulin, cleaved β-2 microglobulin, N-acetyl-beta-D-glu-
cosaminidase, alpha/pi S-glutathione transferase or retinol-
binding protein (RBP) in urine.
Tubular proteins as early markers of TA/IF
development
Tubular proteins such as α-1-microglobulin, β-2 micro-
globulin, N-acetyl-beta-D-glucosaminidase, RBP and the
brush border enzymes alanine-aminopeptidase and gam-
ma-glutamyltransferase are small molecules (between 5
and 40 kDa) that are freely filtered by the glomeruli and
virtually totally reabsorbed by the proximal tubular cells.
They can be found at higher levels in urine when there is
substantial filtration overload that surpasses tubular reab-
sorption capacity (Tm), or when there is tubular dysfunc-
tion allowing less back capture. Small molecular weight
protein catabolism takes place in the proximal tubules
mainly in the S1 and S2 segments of proximal tubules and
less extensively in S3, where these constitute the most
affected areas in ischemic/toxic injuries (33). Although
poorly understood, it is known that tubular proteins are
internalized by the megalin-cubilin-mediated endocytosis
process. Megalin is a 600-kDa transmembrane protein of
the LDL receptor family with NH2 extracellular, single trans-
membrane and short intracytoplasmic domains. Megalin
has been shown to endocytose pro-inflammatory and pro-
fibrotic cytokines as well as a variety of other important
hormones and small proteins, including albumin, prolactin,
insulin, vitamin D-binding protein, RBP, α-1-microglobulin,
and β-2 microglobulin (34). Another key protein, cubilin,
also known as the intestinal intrinsic factor cobalamin
receptor, is a 460-kDa receptor with no transmembrane
domain that requires assembly with megalin for its internal-
ization. Cubilin is the receptor for albumin (together with
megalin), transferrin, and immunoglobulin light chains,
among others (34). Megalin-cubilin complexes are found
in S1 and S2 portions inside the brush border. After liga-
tion, the whole complex is endocytosed. Once inside the
endosomes, the proteins are dissociated from their ligands,
and directed to lysosomes for degradation. Megalin and
cubilin return to the apical membrane surface (34). This
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endocytic process can be affected by immune or toxic
factors. Furthermore, as stated earlier, TGF-β has a nega-
tive effect on this process. Recent data on megalin-knock-
out mice, cubilin-deficient dogs and on patients with muta-
tions in the cubilin gene have illustrated the importance of
this mechanism.
It has been shown that tubular proteinuria is an earlier
marker of proximal tubular dysfunction (PTD), comparable
with urinary detection of phosphate, glucose, and amino
acids. These factors have been extensively studied in
nephrotoxicity related to heavy metals, glomerulonephritis
and diabetic nephropathy (35). Indeed, it has been demon-
strated that excretion of larger amounts of tubular proteins
may precede glomerular involvement in diabetic nephrop-
athy, even before the appearance of microalbuminuria.
Specifically in glomerulonephritis, the presence of high
levels of tubular protein in urine correlates with poor renal
survival and steroid responsiveness (36-38). Thus, the
presence of high urinary levels of small tubular proteins in
a transplant recipient could be a silent marker of tubular
dysfunction, which, if persistent, could herald loss of long-
term graft function (as we will discuss below).
Much has been done in detecting tubular injury by
using new biomarkers in renal transplant patients with
acute rejection. Zhang et al. (39) investigated the specific-
ity of kidney injury molecule-1 (Kim-1) as a marker of
tubular injury in renal transplanted patients with acute
rejection and in protocol biopsies. Kim-1 is a transmem-
brane tubular protein with extracellular immunoglobulin
and mucin domains that so far has no identified functions.
Its soluble ectodomain is released in urine after cleavage,
being considered an excellent marker of proximal tubular
injury induced by ischemic or toxic tubule stresses (40,41).
In their study, Kim-1 was expressed in proximal tubules in
28% of the protocol biopsies although none presented
histological signs of tubular injury. More importantly, Kim-
1 expression correlated with functional outcome of the
graft 18 months later. Similar data were obtained from
those patients with acute rejection. These data demon-
strated that a proximal tubular biomarker can be suffi-
ciently sensitive to detect tubular injury, albeit during a
rejection episode, and can also predict graft outcome (39).
However, the authors did not measure protein in urine or
any other low protein marker simultaneously with the im-
munohistochemistry to assure that this sensitivity was
maintained or could prove useful for clinical surveillance.
Complementary to these data, van Timmeren et al.
(42) did measure Kim-1 expression in urine and in biopsies
of patients with different renal diseases, including glomer-
ulonephritis. They observed that the biomarker correlated
positively with renal damage and negatively with renal
function. Moreover, Kim-1 co-localized with signs of in-
flammation and renal fibrosis. The potential of Kim-1 as a
biomarker of proximal tubular injury was illustrated in sev-
eral other models and in human studies of drug toxicity
(43,44), heavy metal nephropathy (43,45), protein-over-
load nephropathy (46), and polycystic kidney disease (47).
RBP is the specific blood carrier protein for retinol and
retinol acid, which are lipid-soluble vitamins. RBP is syn-
thesized primarily by the liver, and then released into the
blood, where it forms a complex with thyroxine-binding
prealbumin and is distributed to various tissues. RBP plays
a major role in storage and metabolism of vitamin A. Once
RBP molecules are no longer able to interact effectively
with prealbumin, they are excreted through the glomeruli,
reabsorbed and degraded by proximal tubules. As a
biomarker, the measurement of urinary RBP levels offers
advantages over other proteins because its production is
relatively constant. There is no known clinical situation in
which overproduction could lead to abnormal urinary con-
centrations, and the protein is very stable across the whole
range of urinary pH (37). Akin to RBP, α-1-microglobulin is
a 27-kDa glycoprotein synthesized by liver cells involved in
different roles in the body (bacterial adhesion to lithogen-
esis), and stable in acid urine. However, there is also
evidence that it can be detected in glomerular proteinuria
(48). There are commercially available kits for measuring
these glycoproteins, facilitating their use in the out-patient
clinical management of transplant recipients.
Recently, the urinary levels of RBP were shown to assist
in detecting renal dysfunction in heart and kidney transplant
patients, as early as 5 years before overt renal failure
(49,50). Specifically in heart transplant patients, we demon-
strated that higher levels of RBP (>0.400 mg/L) implied a
3.87-fold risk of renal failure over 5 years of follow-up. In that
study, 36 heart transplant recipients with a median age of
43.3 years were evaluated 15 months after surgery. All
patients were under CI therapy. Five patients of 13 with
higher urinary levels of RBP developed end-stage renal
disease that required dialysis. This renal function loss was
mainly due to chronic cyclosporine toxicity. An even greater
impact was seen in renal transplant recipients.
In 92 renal transplant patients with good and stable renal
function at least 3 months after engraftment, 52% were
found to have increased urinary excretion of RBP. Ninety-
two patients were under CI immunosuppression. During a
five-year follow-up period, TA/IF was detected in 23 patients
(25%), 19 (82.6%) of whom had high levels of urinary RBP.
Five-year TA/IF-free and graft survivals were significantly
worse in patients with higher levels of urinary RBP than in
patients with normal levels (57.5 vs 89.9%, P = 0.0004; 70.7
vs 100%, respectively, P = 0.0002). The presence of high
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urinary RBP levels, namely the presence of PTD, was the
strongest factor associated with the development of TA/IF
(RR = 5.3, 95%CI = 1.45-19.58, P = 0.012) compared to
patients with normal urinary levels of RBP (50).
In agreement with these data, Teppo et al. (51,52) have
recently observed that 60% of patients with increased
urinary excretion of α-1-microglobulin at 6 months had
renal function deterioration during a 4-year follow-up pe-
riod. The authors measured 24-h urinary excretion of α-1-
microglobulin, albumin and TGF-β in 79 renal transplant
recipients with an average of 51 months post-transplanta-
tion. The urinary α-1-microglobulin significantly correlated
with urinary TGF-β (r = 0.508), with albumin (r = 0.220), and
with the changes in 24-h creatinine clearance (r = -0.273).
More importantly, they observed that 60% of patients with
an α-1-microglobulin/creatinine ratio greater than 5 mg/
mmol presented a poor long-term outcome, namely renal
function deterioration. It is worth to emphasize that they
have initially shown that a sustained higher ratio of α-1-
microglobulin/creatinine measured in urine predicted AR
in renal transplanted patients and correlated with the dura-
tion of cold ischemia (51,52).
More recently, data from Nickerson’s group (53) dem-
onstrated a role for a specific form of β-2 microglobulin in
graft monitoring. Although, as early described, β-2 micro-
globulin is unstable in low pH urine, this could become
advantageous for patients with acute tubulointerstitial re-
jection. By using proteomic platform analyses, this group
showed that a cleaved form of β-2 microglobulin (cleaved
by aspartic proteases present in the urine of transplanted
patients) was a good indicator of acute tubular injury (53).
There are two main reasons for the high levels of small
tubular protein found in transplant recipients: i) high levels
could be a marker of PTD, as a sign of distress of proximal
tubular cells, or ii) they may be markers of definitive tubular
damage, as a result of tubulointerstitial fibrosis before any
important change in glomerular filtration has occurred. Our
recent data support the former hypothesis. By analyzing
50 renal biopsies from patients with higher (>1 mg/L, N =
13) and normal (N = 37) urinary levels of RBP, we were
able to demonstrate that PTD was associated with 2-year
renal graft functional impairment. At various RBP meas-
urements and from renal biopsy analysis, there was no
expression of α-SMA in proximal tubular cells of those
patients with higher urinary levels of RBP (54).
The near future of biomarkers
Little is known about the molecular pathways underly-
ing the histological features of TA/IF. Microarray is a pow-
erful technique to detect thousands of genes related to
these pathways (55). The identification of these putative
genes is one further step towards the early diagnosis of
TA/IF, and towards better management and prognosis of
these patients (56). Mas et al. (56) used the microarray
technique in kidney samples of transplanted patients with
TA/IF in order to identify new noninvasive diagnostic mark-
ers. Comparing to normal kidneys, they found 728 differen-
tially expressed genes related to fibrosis, extracellular
matrix and inflammation. Moreover, the authors identified
some genes in urine of patients with TA/IF compared to
normal controls with stable renal function (18).
Proteomic techniques have been widely used in recent
years for the discovery of new biomarkers or validation of
established ones in different samples, urine, blood, and
tissues. Using three different experimental models of drug
toxicity, Bandara et al. (57) identified a rat-specific isoform of
kininogen in the plasma of all three models. Interestingly,
alpha-1 macroglobulin was up-regulated after cisplatin treat-
ment and RBP was down-regulated in the plasma after D-
serine therapy. Unfortunately, the group did not study these
proteins in urine in order to certify their expression.
Proteomics is a growing field in transplantation due to
the higher expectations of new biomarker discoveries in
acute rejection and in TA/IF pathologies. Urinary prote-
omic analyses have already been shown to identify a
specific profile in acute rejection with more than 90%
sensitivity (58,59). Its role in detecting proximal tubular
dysfunction is totally undefined, although it has long been
established that this condition alters the profile of urinary
proteins compared to normal urinary proteome. An elegant
study was performed by Cutillas et al. (60) in patients with
Dent’s disease, an X-linked recessive proximal tubular
disorder due to mutations in the chloride/proton exchanger
gene, CLCN5, in which the cubilin-megalin apparatus is
ineffective. The authors identified a broad range of low
molecular weight proteins, including RBP, β-2 glycopro-
tein-I and vitamin D-binding protein, which were differen-
tially expressed, thus demonstrating the increasing poten-
tial of proteomic technology in detecting PTD.
In summary, although much effort is currently being
directed toward preservation of renal allograft function
once TA/IF has been detected, or preemptively, to avoid its
occurrence by employing individualization of the immuno-
suppressive scheme (avoidance of CI), the ideal strategy
by which the development of TA/IF could be eliminated
altogether remains the missing link. We believe that enough
information is available to recommend clinical trials that
would help to modify drug regimes and clinical manage-
ment accordingly. Small tubular proteins can easily be
measured in urine and are highly reliable in predicting
long-term graft function.
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